复方甲巯咪唑软膏中甲巯咪唑及氢化可的松体外透皮释药研究

 目的：测定不同基质、不同主药浓度、不同渗透促进剂的各种软膏中他巴唑及氢化可的松的体外透皮释药率，评价各因素对主药经皮渗透的影响。方法：用改良Franz垂直扩散池，HPLC测定。结果：A型、B型基质软膏中，他巴唑的透皮释药率分别为49.10%，29.83%(P＜0.05);氢化可的松的透皮释药率分别为3.17%,1.59%(P＜0.05)。有或无月桂氮酮的软膏中，他巴唑的透皮释药率分别为49.10%,54.14%(P＞0.05),氢化可的松的透皮释药率分别为3.17%,1.61%(P＜0.05)。结论：o/w型基质较w/o型基质更有利于他巴唑及氢化可的松的经皮渗透。月桂氮酮对他巴唑无明显的促进渗透作用，但可提高氢化可的松的经皮渗透率1.92倍。

Methimazole ointment compound:percutaneous release of methimazole and hydrocortson in vitro

To determine the percutaneous release of methimazole and hydrocortson in different stroma,permeation enhancers,their consistency in vitro,and evaluate the factors affecting drug release,METHOD:The vertical Franz diffusion cell was applied.The samples were analyzed by HPLC. RESULTS:In stroma A and B,the release rate of methimazole was 49.10%and 29.83%(P<0.05)respectively. In stroma A and B,the release rate of hydrocortison was 3. 17%and l.59%(P<0.05)respectively.In the ointment with laurocapram or without laurocapram,the release rate of methimazole was 49.10%and 54.15%(P>0.05),respectively. In the ointment with laurocapram or without,the release rate of hydrocortison was 3.17%and l.61%(P<0.05)respectively.CONCLUSION:Stroma o/w was more beneficial to the percutaneous permeation of the drug than stroma w/o. The effect of laurocapram was not obvious for methimazole.The laurocapram had certain penetrative accelerating effect on hydrocortison,and could raise the release rate for l.92 times.